{"title":"Effect of single intravitreal triamcinolone acetonide injection on intraocular pressure and retinal nerve fibre layer thickness","authors":"Shazia Arrin, Simi Zaka-ur-rab","doi":"10.33545/26638266.2021.v3.i1a.80","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the intraocular pressure (IOP) changes following intravitreal triamcinolone acetonide (IVTA) injection for inflammatory, proliferative and edematous diseases of posterior segment of eye. Design: Prospective longitudinal interventional study. Methods: The prospective longitudinal study included 30 with posterior uveitis (n=12), retinal vascular occlusive diseases (n=10), Eales’ disease (n=6), pseudophakic cystoid macular edema (n=1) and idiopathic cystoid macular edema (n=1). 4 mg of IVTA injection IOP increased significantly from baseline IOP of 14.27±3.53 mm Hg to mean IOP of 16.54± 4.29, 18.54± 5.50, 19.00± 5.98, 18.82± 5.00 and 22.50±0.71 mm Hg at 2, 4, 6, 8 and 12 weeks follow up respectively. In study group IOP elevation of ≥6 mm Hg from baseline was seen in 17 out of 30 eyes (64.71% males and 35.29%females). The majority of patients belonged to younger age group. An IOP elevation was seen in 58.82% and 88.24% eyes upto 4 and 6 weeks follow up respectively. In 15 out of 17 eyes, IOP was controlled with topical anti-glaucoma medications while 2 eyes required filtering glaucoma surgery. Conclusions: After 4 mg of IVTA injection 57.67% of eyes developed IOP elevation ≥6 mm Hg from baseline. In 88.24% eyes raised IOP was controlled with topical anti-glaucoma medications. There was no statistically significant change observed in retinal nerve fibre layer thickness upto 12 weeks follow up, despite elevated IOP. Besides glaucoma no other complication was observed upto 12 weeks of follow up.","PeriodicalId":14021,"journal":{"name":"International Journal of Medical Ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33545/26638266.2021.v3.i1a.80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To investigate the intraocular pressure (IOP) changes following intravitreal triamcinolone acetonide (IVTA) injection for inflammatory, proliferative and edematous diseases of posterior segment of eye. Design: Prospective longitudinal interventional study. Methods: The prospective longitudinal study included 30 with posterior uveitis (n=12), retinal vascular occlusive diseases (n=10), Eales’ disease (n=6), pseudophakic cystoid macular edema (n=1) and idiopathic cystoid macular edema (n=1). 4 mg of IVTA injection IOP increased significantly from baseline IOP of 14.27±3.53 mm Hg to mean IOP of 16.54± 4.29, 18.54± 5.50, 19.00± 5.98, 18.82± 5.00 and 22.50±0.71 mm Hg at 2, 4, 6, 8 and 12 weeks follow up respectively. In study group IOP elevation of ≥6 mm Hg from baseline was seen in 17 out of 30 eyes (64.71% males and 35.29%females). The majority of patients belonged to younger age group. An IOP elevation was seen in 58.82% and 88.24% eyes upto 4 and 6 weeks follow up respectively. In 15 out of 17 eyes, IOP was controlled with topical anti-glaucoma medications while 2 eyes required filtering glaucoma surgery. Conclusions: After 4 mg of IVTA injection 57.67% of eyes developed IOP elevation ≥6 mm Hg from baseline. In 88.24% eyes raised IOP was controlled with topical anti-glaucoma medications. There was no statistically significant change observed in retinal nerve fibre layer thickness upto 12 weeks follow up, despite elevated IOP. Besides glaucoma no other complication was observed upto 12 weeks of follow up.
目的:探讨曲安奈德(IVTA)治疗眼后段炎症性、增生性和水肿性疾病后玻璃体内注射曲安奈德后眼压(IOP)的变化。设计:前瞻性纵向介入研究。方法:前瞻性纵向研究包括30例后葡萄膜炎(n=12)、视网膜血管闭塞性疾病(n=10)、Eales病(n=6)、假性晶状体囊样黄斑水肿(n=1)和特发性囊样黄斑水肿(n=1)。在随访2、4、6、8、12周时,IVTA注射4 mg的IOP分别从基线的14.27±3.53 mm Hg升高至16.54±4.29、18.54±5.50、19.00±5.98、18.82±5.00和22.50±0.71 mm Hg。在研究组中,30只眼中有17只眼眼压比基线升高≥6 mm Hg(64.71%为男性,35.29%为女性)。患者以低龄组居多。随访4周和6周时,眼压升高分别为58.82%和88.24%。在17只眼睛中,有15只眼睛的眼压通过局部抗青光眼药物控制,而2只眼睛需要进行滤过性青光眼手术。结论:注射4 mg IVTA后,有57.67%的眼眼压较基线升高≥6 mm Hg。88.24%的眼压升高者使用局部抗青光眼药物控制眼压。尽管IOP升高,但随访12周后,视网膜神经纤维层厚度无统计学意义变化。随访12周,除青光眼外未见其他并发症。